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Interferon-producing killer dendritic cells (IKDC) were first described for their outstanding
anti-tumoral properties.The “IKDC” terminology implied the description of a novel DC sub-
set and initiated a debate on their cellular lineage origin.This debate shifted the focus away
from their notable anti-tumoral potential. IKDC were recently redefined as precursors to
mature NK (mNK) cells and consequently renamed pre-mNK cells. Importantly, a putative
human equivalent of pre-mNK cells was recently associated with improved disease out-
come in cancer patients. It is thus timely to revisit the functional attributes as well as the
therapeutic potential of pre-mNK cells in line with their newly defined NK-cell precursor
function.
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INTRODUCTION
The immune system forms an elaborate network of multiple cell
types which together collaborate to eliminate unwanted pathogens
and tumor cells. Among immune cells, natural killer (NK) cells
demonstrate rapid cytotoxic activity upon the first signs of infec-
tions or cellular transformation (1, 2). The cellular particles and
debris resulting from NK cell-mediated lysis are rapidly engulfed
by the neighboring dendritic cells (DC) (3). DC are specialized
antigen-presenting cells, which process and present antigens to T
cells, thereby initiating the adaptive arm of the immune response
(4). DC and NK cells are thus essential components of the innate
immune system.
Interestingly, unique cell types conjugating properties of both
NK cells and DC have previously been described (5, 6). In humans,
activated NK cells have been reported to express MHC class II and
present antigens to T cells (7–10). Conversely, in humans and in
rodents, some DC subsets exhibit cytolytic activity (11–20). More
recently, a murine cell type exhibiting properties of both NK and
DC was identified and named interferon-producing killer den-
dritic cells (IKDC) (21, 22). As for NK cells, IKDC exhibit the
capacity to produce IFN-γ and to mediate cytotoxic activity and,
as for DC, they efficiently present antigens and stimulate T cell
responses (21, 22). The combination of these unique properties
endows IKDC with a unique immune potential allowing to specif-
ically bridge functions of the innate and adaptive immune system.
The outstanding biological potency of IKDC was rapidly noted
in various in vivo tumoral settings (22–24). However, the study
of IKDC for their anti-tumoral properties was rapidly halted as
a debate emerged regarding both the cellular lineage origin of
IKDC and their hybrid cellular properties (5, 25–29). IKDC have
now been recognized as part of the NK-cell lineage (26–28, 30) and
have since been renamed pre-mature NK (mNK) cells (30, 31). As
the debate on the lineage origin comes to a close, the means by
which pre-mNK cells carry out the elimination of tumors needs
to be revisited. Further understanding the biological attributes of
pre-mNK cells which confers them this prominent anti-tumoral
potential may improve the design of cancer therapies. A case in
point, the presence of a putative human equivalent of pre-mNK
cells is positively associated with improved disease outcome in
patients affected by refractory solid tumors (32). We herein review
the origin of the controversy with regards to the lineage origin
and function of pre-mNK cells. In addition, we present the anti-
tumoral activity of pre-mNK cells in line with their new mNK-
cell precursor function, as well as discuss the identification and
biological attributes of the suggested human cellular equivalent.
PRE-mNK CELLS AS PART OF THE NK LINEAGE
Pre-mNK cells, for their initial name“IKDC,”were first considered
as a new DC subset (21, 22). Initial comparative gene expression
profile arrays, ultrastructure analysis with electron microscopy,
and evaluation of many cell surface markers by flow cytometry
suggested a close phenotypic relationship between pre-mNK cells
and plasmacytoid DC (pDC) (21, 33) (Figure 1). However, it was
subsequently shown that pre-mNK cells represent a unique cell
subset more closely related to NK cells (26–28) (Table 1). For
one, both mNK and pre-mNK cells are dependent on the Id-2
transcription factor, whereas, in stark contrast, overexpression of
Id-2 inhibits pDC differentiation (34, 35). Also, NK cells and pre-
mNK cells are absent in Il15−/−, Il15ra−/−, Rag2−/−Il2rg−/−, and
Rag2−/−Il15−/−mice, highlighting their common dependency on
IL-15 for differentiation (26, 28, 36). Moreover, it was found that
the CD11clow B220+ cell surface phenotype was not exclusive to
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FIGURE 1 | Pre-mNK cells share phenotypic expression with a variety
of other immune cells. Murine immune cell types harboring cell surface
antigens also present on pre-mNK cells are depicted. The intensity in color
represents the level of expression. Note that a combination of at least three
cell surface antigens, namely CD11c, B220, and CD49b, must be used to
clearly distinguish pre-mNK cells from other immune cell types. This shared
phenotypic character of pre-mNK cells increases the risk of potential
cellular contaminants during the isolation process.
pDC and pre-mNK cells. Indeed, upon in vitro activation, NK cells
can also acquire the expression of both CD11c and B220 antigens,
as well as the expression of several additional cell surface antigens
previously thought to specifically distinguish pre-mNK cells from
NK cells, namely CD69, CD86, MHCII, FasL, and CD44 (28, 37–
40). Furthermore, in vitro activated NK cells, as for pre-mNK cells,
produce high levels of IFN-γ and exhibit an enhanced cytolytic
potential relative to unstimulated NK cells (26, 28, 41). Finally, a
parallel can be drawn between pre-mNK cells and the CD56bright
NK-cell subset in humans, which has been reported to produce
vast amounts of IFN-γ and has also been shown to express MHC
II, at least in some experimental settings (7–10, 42, 43). Therefore,
these observations strongly suggest that pre-mNK cells are not
closely related to pDC. Rather, they appear to represent a subset
of NK cells likely to have been recently activated.
PRE-mNK CELLS AS PART OF THE NK-CELL DIFFERENTIATION
PATHWAY
Pre-mNK cells exhibit similar phenotypic and functional attrib-
utes to in vitro activated mNK cells. Hence, our group recently
designed experiments to address the in vivo biological relationship
between pre-mNK cells and mNK cells (30). We first showed that
pre-mNK cells are not merely activated mNK cells. Indeed, upon
in vivo activation with either anti-CD40 or poly I:C, mNK cells
did not yield cells carrying the pre-mNK cell phenotype. Instead,
we observed that, upon in vivo transfer, pre-mNK cells rapidly
lose B220 expression and exhibit a parallel increase in the expres-
sion of cell surface antigens associated with NK-cell maturation,
ultimately acquiring the phenotype of mNK cells. In contrast to
the in vitro results which suggest that pre-mNK cells are acti-
vated mNK, the in vivo data demonstrate that pre-mNK cells are
precursors to mNK cells.
The apparent discrepancy between the phenotype and func-
tion of pre-mNK cells described in both the in vitro and in vivo
setting can likely be explained by variations in the experimental
conditions. Firstly, NK cells sorted for in vitro culture comprise
a pool of both pre-mNK cells and mNK cells which are subject
to non-physiological stimuli such as high doses of IL-2. These
conditions may favor the survival of pre-mNK cells in vitro, allow-
ing for an accumulation of B220+ CD49b (DX5)+ NK cells over
time. This is rather unlikely as pre-mNK cells were shown to
rapidly undergo apoptosis upon in vitro culture (27). Alterna-
tively, B220 expression may be artificially up-regulated on mNK
cells upon exposure to non-physiological stimuli in the in vitro
setting. It remains to be seen whether B220+ mNK cells generated
upon in vitro culture are equivalent to pre-mNK cells obtained
in vivo. Secondly, upon in vivo transfer, sorted B220− mNK cells
did not acquire a pre-mNK cell phenotype in response to either
anti-CD40 or poly I:C treatment. Admittedly, it is possible that
other in vivo stimuli may allow mNK cells to acquire the pre-
mNK cell phenotype. For instance, imatinib mesylate (IM) and
IL-2 or IL-15 trans-presentation, which increase the proportion
of pre-mNK cells in vivo (22, 36, 44), may facilitate mNK cells
to acquire the pre-mNK cell phenotype. Altogether, the in vitro
and in vivo data suggest that the pre-mNK cell phenotype may
be acquired through different means. Regardless, in vivo, pre-
mNK cells are precursors to mNK cells as they exhibit a close
transcriptome relationship to the first stages of mNK cell differ-
entiation and they can effectively generate mNK cells upon in vivo
transfer (30).
Mature NK cells are derived from hematopoietic stem cells in
the bone marrow which undergo a series of specific and highly
guided differentiation events to eventually yield functional mNK
cells (Figure 2). Interestingly, prior studies identified an NK-cell
precursor population in the bone-marrow expressing a pheno-
type similar to pre-mNK cells, namely B220+ CD19− CD43+
CD24− BP-1 (Ly-51)− cells (45). Although the level of CD11c
expression had not been assessed, these cells likely define what
is now known as pre-mNK cells, suggesting that pre-mNK cells
are also found in the bone marrow. The earliest identified NK
cell-committed progenitor are termed pre-NKP cells and arise
from the common lymphoid progenitors (CLP) (46). Impor-
tantly, these cells have yet to express CD122 (IL-2Rβ), suggesting
that this early NK-cell differentiation event is independent of the
IL-15 cytokine (46). Pre-NKP cells subsequently generate NKP
which differentiate into iNK cells. iNK cells express NK1.1 and
gradually acquire CD49b expression as they differentiate into
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Table 1 | Properties of pre-mNK cells relative to pDC and NK cells.
pre-mNK cells pDC mNK cells Activated NK cells
DIFFERENTIATION
Id-2 Yes No Yes Yes
IL-15 Yes No Yes Yes
γc Cytokines Yes No Yes Yes
Flt3L + +++ ++
PU.1 No Yes No No
RelB Yes Yes No No
IRF8 Partially Yes No No
FUNCTION
IFN-γ production +++ − + +++
IL-12 production + ++ − −
IFN-α production − +++ − −
Killing mechanism TRAIL and NKG2D-dependent No Perforin/granzyme-dependent Perforin/granzyme-dependent
Cytotoxic activity +++ − + +++
Antigen presentation + + − +
ANTIGENIC PHENOTYPE In vivo In vitro
CD11c Low Low No/low No/low Low
B220 High High − − High
CD49b + − + + +
CD122 + − + + +
NK1.1 + − + + +
CD43 + −/+ +++ +++ +++
Ly108 +++ −/+ − − −
CD27 High − Low/high Low/high Low/high
CD11b Low/high − Low/high Low/high Low/high
MHC II + (in LNs)/− (in spleen) + − + +
CD69 + − − + +
CD86/CD80 + (in LNs)/− (in spleen) + − − −
CHARACTERISTICS
Proliferation ++++ + + ++
mNK cells. Interestingly, a small proportion of iNK cells express
B220 suggesting that this marker is slowly acquired en route to
becoming an mNK cell (28). Based on their phenotypic charac-
terization, the CD11clow B220+ CD49b+ pre-mNK cells are likely
to immediately follow the iNK cell stage and, as such, define a
late intermediary stage in mNK cell differentiation (Figure 2).
The functional maturation of mNK cells can be further sub-
divided into four stages according to the relative expression of
CD27 and CD11b (47), namely stage 1 CD11blowCD27low, stage
2 CD11blowCD27high, stage 3 CD11bhighCD27high, and stage 4
CD11bhighCD27low. Still, whether pre-mNK cells present an oblig-
atory or an alternative stage in mNK cells differentiation needs to
be resolved. Of interest, while iNK cells produce stage 1 mNK
cells, pre-mNK cells appear to differentiate directly into stage
2 mNK cells (30, 47). Therefore, pre-mNK cells may reflect an
alternate differentiation pathway arising from iNK cells which
can either generate stage 1 mNK cells or pre-mNK cells. Alter-
natively, pre-mNK cells have been proposed to arise directly from
L-selectin progenitors (LSP), while mNK cells were mostly pro-
duced from CLP and ELP (34). Pre-mNK cells may altogether
define a novel alternate pathway for mNK cell differentiation
(Figure 2).
The most striking feature distinguishing pre-mNK cells from
mNK cells is the expression of B220. Interestingly, there is evi-
dence that B220 (an alternatively spliced and heavily glycosylated
product of Cd45) contributes toward defining the number of
mNK cells in secondary lymphoid organs, as well as their ability
to produce cytokines. Indeed, NK-cell numbers are increased in
CD45-deficient mice, and CD45-deficient NK cells show a selective
impairment in ITAM-based receptor cytokine production (48–
50). Hence, it is tempting to suggest that lack of B220 expression
deregulates pre-mNK cells, thereby promoting an altered NK-cell
differentiation pathway. More studies are required to assess how
pre-mNK cells and how B220 contribute toward defining the size
of the NK-cell niche.
Interestingly, thymic NK-cell differentiation is defined as a dis-
tinct pathway generating mNK cells in secondary lymphoid organs
(51, 52). These thymic-derived mNK cells can be distinguished
based on the expression of CD127 (IL-7Rα) and GATA-3 (51)
(Figure 2). Notably, neither pre-NKP nor pre-mNK cells seem
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FIGURE 2 | Positioning pre-mNK cells in the NK-cell differentiation
pathway. NK-cell differentiation is a multi-step process, wherein cellular
intermediates can be distinguished based on the acquisition and loss of the
expression of specific cell surface antigens, in mice. Pre-NKP cells
represent the earliest defined mNK cell-committed progenitor. Here,
pre-mNK cells are positioned as a cellular intermediate following iNK cells
and preceding mNK cells. Question marks indicate differentiation steps that
remain to be experimentally verified. The thymic-derived pathway is also
depicted.
to be implicated in this pathway; intrathymic injections of pre-
NKP cells do not generate mNK cells, whereas pre-mNK cells are
virtually undetectable in the thymus and do not express CD127
(21, 46). Still, most stage 1 mNK cells in the secondary lymphoid
organs express CD127 and are absent in Rag-deficient mice (30,
47, 51). Together, these results suggest that most stage 1 mNK cells
may be derived from thymic precursors. The relationship between
the cellular intermediates of each of these NK-cell differentiation
pathways has yet to be fully elucidated. Moreover, the type of mNK
cells generated from each of these distinct pathways, as well as the
specific cellular intermediates, such as CD127+-thymic-derived
NK cells and pre-mNK cells, may play specific roles in the immune
response.
THE ROLE OF PRE-mNK CELLS IN THE ANTI-TUMORAL
IMMUNE RESPONSE
Apart from defining an intermediate cell type in the NK-cell
differentiation pathway, pre-mNK cells have been primarily stud-
ied for their remarkable anti-tumoral potential, which was first
uncovered by the group of Zitvogel (22). They demonstrated that
pre-mNK cells, and not conventional mNK cells, are responsible
for the anti-tumoral response after a treatment with IM in com-
bination with IL-2 (22). Indeed, the adoptive transfer of IM and
IL-2-stimulated pre-mNK cells dramatically impaired melanoma
tumor outgrowth in immunodeficient (Rag2−/−Il2rg−/−) mice
(22). Interestingly, a similar treatment composed of IM and IL-
2 increased the proportion and number of a putative human
equivalent to pre-mNK cells, namely HLA-DR+ NK cells, in can-
cer patients and was associated with a better prognostic (32,
53). Additional studies using distinct tumor models and different
mouse strains corroborated the remarkable anti-tumoral poten-
tial of murine pre-mNK. Notably, the injection of bone-marrow
(BM)-derived pre-mNK cells inhibited syngeneic tumor growth
in C57BL/6 and beige mice (23).
The anti-tumoral potential of pre-mNK cells is mediated in
part by their propensity to effectively secrete elevated quantities of
cytopathic cytokines relative to mNK cells (22, 24). Indeed, IFN-γ
production by pre-mNK cells can be triggered by IL-12, IL-15, IL-
18, and/or various combinations of these cytokines (21, 26, 54).
Other factors such as CPG ODN, poly I:C, TLR agonists can also
promote IFN-γ production by pre-mNK cells (24, 54). Moreover,
tumor cells expressing NKG2D ligands can induce IFN-γ produc-
tion by pre-mNK cells (23). Other than IFN-γ, pre-mNK cells have
been reported to also produce more TNF-α than mNK cells (26).
Of note, pre-mNK cells were previously shown to produce IFN-α
(21), but this was not confirmed (26, 54). It was proposed that
the initial preparation of pre-mNK cells may have been contami-
nated with pDC which bear a similar phenotype to pre-mNK cells
(Figure 1) and are known to produce vast amounts of IFN-α in
response to various stimuli (26, 54). Overall, pre-mNK cells have
been mostly studied for their ability to produce more IFN-γ than
mNK cells (22).
Additional in vitro and in vivo manipulations of pre-mNK
cells have revealed that the cytotoxic activity toward tumoral cells
and the antigen-presentation potential to T cells are likely to
be uncoupled. It appears that activation of pre-mNK cells with
cytokines primes them for enhanced cytolytic potential, whereas
interaction with at least some tumoral cell types promotes their
antigen-presentation potential (Figure 3). For instance, IL-15 sig-
nificantly contributes to the anti-tumoral potential of pre-mNK
cells, as demonstrated by the decrease of pre-mNK cell effec-
tiveness in Il15−/− mice (55). Enhancing the in vivo expression
of IL-15 by hydrodynamic injection of a IL-15-expressing cas-
sette also potentiates the number of pre-mNK cells as well as
enhances their cytolytic activity (44) (Figure 3). Activated pre-
mNK cells have the capacity to kill a murine lymphoma cell line
(YAC-1), an MCMV protein expressing cell line (Ba/F3-m157)
as well as a melanoma murine tumor cell line (B16F10) (21,
22). The cytotoxic activity of pre-mNK cell is dependent on
NKG2D expression and is mediated by TRAIL receptors, in con-
trast to mNK cells, which preferentially use the perforin/granzyme
pathway (22, 36). In addition, in vitro IL-15-stimulated pre-
mNK cells express unique biological functions and these are not
shared by B220− mNK cells (36). Indeed, in contrast to mNK
cells, IL-15-stimulated pre-mNK cells show an improved response
to type 1 IFN and IL-2 facilitating their migration into tumor
beds in a CCL2-dependent manner (36, 55). Moreover, IL-15-
stimulated pre-mNK cells acquire resistance to TGF-β induced
immunosuppression (36). However, IL-15-stimulated pre-mNK
cells lose the capacity to induce MHC class I or II-restricted
T cell activation in vitro. Altogether, these results indicate that
high doses of IL-15 is an efficient means to expand anti-tumoral
pre-mNK cells, while inhibiting their antigen-presentation
potential.
In contrast, the antigen-presentation potential of ex vivo iso-
lated pre-mNK cells appears to be restricted to CD11b+ pre-mNK
cells (56) (Figure 3). Specifically, the CD11b+ pre-mNK cells have
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FIGURE 3 | Described murine phenotypes of pre-mNK cells. This figure
illustrates the different described phenotypes of pre-mNK cells. The top
left image represents pre-mNK cells which have the capacity to present
antigens to both CD4+ and CD8+ T cells. Antigen-presenting pre-mNK cells
express CD11b and CD206, a mannose receptor implicated in the uptake
of antigens. The top right image depicts cytotoxic pre-mNK cells obtained
through the trans-presentation of IL-15. IL-15 promotes pre-mNK cells to
actively transcribe several genes, thus enhancing IFN-γ production,
cytolytic potential, and upregulating the expression of chemokines
receptors on pre-mNK cells which facilitates the recruitment at tumor
sites. The bottom left image portrays ex vivo isolated primary pre-mNK
cells, which express high levels of Ly108 and low levels of CD43. Primary
pre-mNK cells acquire an mNK cell phenotype upon in vivo transfer. The
bottom right image illustrates that bone-marrow pre-mNK cells can be
recruited to the tumor environment by an unidentified mechanism. Upon
killing of a tumor cell, these bone-marrow pre-mNK cells are licensed to
cross-present tumor antigens to T cells, initiating the adaptive immune
response.
the capacity to directly prime naive CD4+ T cells or cross-present
soluble antigens to naïve CD8+ T cells in a CD206 (mannose
receptor C type 1, MRC1) and B7-dependent manner. Impor-
tantly, the antigen-presentation potential of pre-mNK cells was
revealed in this study upon exposure of pre-mNK cells to tumoral
cells.
Similarly, the antigen-presentation potential of pre-mNK cells
was shown to be potentiated in pre-mNK cells arising from a BM-
derived in vitro cell culture exposed to tumor cells (Figure 3).
Indeed, to investigate the anti-tumoral role of BM-derived-DC,
Anderson’s group studied pre-mNK cells present in the BM-DC
preparation, likely arising in the culture due to the physiolog-
ical production and trans-presentation of IL-15 by BM-DC in
response to GM-CSF (57, 58). The pre-mNK cells accounted for
the anti-tumor activity against 76-9:C23 alveolar rhabdomyosar-
coma, as removing pre-mNK cells lead to the loss of the tumo-
ricidal activity (23). Importantly, this approach generated vast
numbers of viable BM-derived pre-mNK cells, allowing their spe-
cific investigation in both in vitro and in vivo settings. To that
effect, the adoptive transfer of BM-derived pre-mNK cells could
inhibit 76.9 tumor growth in B6 mice but not in immunode-
ficient tumor-bearing host mice showing that BM-derived pre-
mNK cells are dependent on the presence of the adaptive immune
system for tumor rejection, again supporting their role in antigen-
presentation (23, 59). These results contrast with those showing
anti-tumoral activity of pre-mNK cells in Rag2−/−Il2rg−/− mice
carrying established melanomas, suggesting that BM-derived pre-
mNK cells may have different migratory or functional properties
to that of pre-mNK cells isolated from a spleen (22). Alternatively,
alveolar rhabdomyosarcoma or melanoma may induce distinct
biological responses from pre-mNK cells. In a subsequent study,
BM-derived pre-mNK cells were shown to migrate out of tumor
beds toward tumor draining lymph nodes, where they expressed
MHC II and costimulatory molecules (59). Altogether, Anderson’s
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group propose a model where BM-derived pre-mNK cells migrate
to the tumor site to lyse tumor cells, take up released tumor anti-
gens, and then present these antigens in the draining lymph nodes.
This model is in agreement with the first publication on pre-
mNK cells by Housseau’s group showing that pre-mNK cells have
specialized function in specific locations (21).
IN VIVO INVESTIGATIONS OF PRE-mNK CELLS IN
NON-TUMORAL IMMUNOLOGICAL RESPONSES
The immunological potential of pre-mNK cells has also been
investigated in the context of viral responses and autoimmunity,
extending the therapeutic potential of pre-mNK cells to other
clinical settings.
To our knowledge, only two studies have attempted to unravel
the role of pre-mNK cells in the context of viral responses. First,
the human immunodeficiency virus (HIV) was shown to induce
cells bearing phenotypic and functional similarity to mouse pre-
mNK cells (60). Yet, their role in controlling the viral response
has not been investigated. Second, in a mouse model of influenza,
pre-mNK cells were shown to exhibit similar functional prop-
erties to mNK cells in regulating the immune response in the
lung. Both pre-mNK cells and mNK cells presented viral antigens
to CD8+ but not CD4+ T cells and simultaneous depletion of
both pre-mNK and mNK cells using anti-NK1.1 antibody inhib-
ited the expansion of viral-specific CD8+ T cells but had no
effect on viral clearance (29). Interestingly, in support of a role
for pre-mNK cells in presenting antigens to T cells in the con-
text of infection, cytomegalovirus-infected fibroblasts were also
shown to increase MHC II expression on pre-mNK cells as well
as cross-present antigens to CD8 T cells (61). This finding is
reminiscent of a study with human NK cells, where exposure to
infected cells increases their antigen-presentation potential to T
cells (9). Still, additional studies of pre-mNK cells in infectious
models based on mNK cell-dependent viral clearance are needed
to unravel the specific role of pre-mNK cells in viral responses.
As such, it would be of interest to verify if, in the context of
chronic viral infections, pre-mNK cells can replenish an exhausted
NK-cell pool.
Pre-mNK cells were also shown to modulate autoimmune
responses. The first evidence for a role of pre-mNK cells in pre-
venting autoimmune responses was obtained in a virally induced
autoimmune-diabetes model (62), adding credence to a potential
anti-viral role for pre-mNK cells. Specifically, a bitypic NK/DC
population, similar in phenotype to pre-mNK cells, was shown to
prevent autoimmune diabetes in the RIP-LCMV mouse model,
where diabetes is induced upon LCMV viral infection (62).
Notably, the tolerogenic anti-CD40L (CD154) treatment increased
the proportion and function of the bitypic NK/DC, which produce
high levels of IFN-γ, exhibit an impressive cytotoxic activity, and
demonstrate proficient antigen-processing and presentation to T
cells. In this setting, it remains to be seen whether the bitypic
NK/DCs prevent autoimmune diabetes by disrupting the ongo-
ing autoimmune or viral response. The second indirect evidence
in support of a role for pre-mNK cells in preventing autoim-
mune diabetes arose from an immunogenetic study, wherein it was
shown that pre-mNK cell number is low in autoimmune-diabetes
prone NOD mice relative to other non-autoimmune-prone inbred
mouse strains (63). The low number of pre-mNK cells in NOD
mice is linked to a small genetic region on distal end of mouse
chromosome 7. This genetic interval had previously been associ-
ated to diabetes resistance and inflammatory responses (63–65).
Interestingly, NOD.Lc7 mice, congenic for the distal end of mouse
chromosome 7 are resistant to autoimmune diabetes and exhibit a
restored number of pre-mNK cells in secondary lymphoid organs.
Hence, it is tempting to suggest that pre-mNK cells confer autoim-
mune resistance in the NOD.Lc7 strain. A third study providing
additional evidence that pre-mNK cells play a protective role in
autoimmune diseases exploited the murine experimental autoim-
mune encephalomyelitis (EAE) model of multiple sclerosis (66).
In this study, pre-mNK cells pre-treated with a tolerizing agent had
the capacity to significantly lower the clinical scores of EAE as well
as to contribute to EAE remission (66). The induction of tolerance
was mediated by the ability of pre-mNK cells to kill activated CD4+
T cells and mature DCs as well as to recruit T regulatory cells to the
CNS (66). This study was the first to describe a potential biological
pathway by which pre-mNK cells may contribute to immune tol-
erance. Although few studies have investigated the potential role of
pre-mNK cells beyond their anti-tumoral response, we believe that
the clearer definition of pre-mNK cells as precursors of mNK cells
will prompt additional investigation of pre-mNK cells in various
immunological settings.
KEY OUTSTANDING QUESTIONS
“Interferon-producing killer dendritic cells” have been redefined
as NK-cell precursors and, consequently, they have been renamed
pre-mNK cells (30, 31). A potentially equivalent cell type has also
been identified in humans and, in both mice and humans, pre-
mNK cells display a potent anti-tumoral potential (22, 32, 56, 59).
In light of these recent findings, here are the key outstanding ques-
tions with regards to pre-mNK cell biology and their therapeutic
potential.
1. Are pre-mNK cells part of an alternate mNK cell differentiation
pathway? Pre-mNK cells are able to generate mNK cells. How-
ever, the step preceding pre-mNK cells has not been defined.
Additional experiments are required to determine whether iNK
cells can generate pre-mNK cells or whether pre-mNK cells
arise from a different pathway.
2. What is the nature of the mNK cells produced from pre-mNK
cells? The mNK cells generated from pre-mNK cells may exhibit
a distinct anti-tumoral potential in comparison to total mNK
cells, which also comprise mNK cells derived from iNK cells
as well as from the thymus. In agreement with functional
segregation of mNK cells based on their origin, it should be
noted that thymic-derived mNK cells specialize in cytokine
production (51, 52). The functional attributes of mNK cells
derived from pre-mNK cells will need to be assessed. One
could speculate that mNK cells generated from pre-mNK cells
could bear enhanced cytotoxic properties and be particularly
geared toward anti-tumoral responses (51). In support of this
view, the anti-tumoral potential of in vivo transferred pre-mNK
cells was mostly TRAIL-dependent (22). A direct comparison
of thymic-derived, iNK-derived and pre-mNK-derived mNK
cells will help determine whether the alternate differentiation
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pathways lead to a common mNK cell fate or to distinct
mNK cell phenotypes, each exhibiting unique functional
characteristics.
3. Is the heightened anti-tumoral potential of pre-mNK cells rela-
tive to mNK cells due to their capacity to generate vast numbers
of mNK cells? Pre-mNK cells as precursors to mNK cells have
the capacity to generate mNK cells. Yet their efficiency at gen-
erating mNK cells in vivo in the context of an inflammatory
response has not been documented. Pre-mNK cells may be
more effective than mNK cells on a per cell basis simply due
to the propensity of pre-mNK cells at generating a larger num-
ber of effective mNK cells in vivo. Interestingly, the suggested
human equivalent to pre-mNK cells, HLA-DR+ NK cells, is
highly proliferative suggesting that they are poised to efficiently
yield high numbers of mNK cells (43). The in vivo experi-
ments comparing the potential of pre-mNK cells and mNK
cells at inducing tumor regression were monitored over several
days, providing sufficient time for pre-mNK cells to potentially
generate large quantity of mNK cells. However, the ability of
pre-mNK cells to generate mNK cells was not quantified over
time in the tumoral settings. Therefore, although pre-mNK
cells proliferate rapidly and are able to generate mNK cells,
their proficiency to do so in an inflammatory setting has yet to
be assessed (30).
4. Is the heightened anti-tumoral potential of pre-mNK cells rel-
ative to mNK cells due to their unique functional attributes?
Pre-mNK cells themselves may exhibit unique immunological
properties conferring them a greater anti-tumoral potential on
a per cell basis relative to mNK cells. Indeed, in contrast to the
non-inflammatory setting where pre-mNK cells rapidly acquire
an mNK cell phenotype, pre-mNK cells maintain their phe-
notype in an inflammatory context (30). Inflammation may
abrogate pre-mNK cell differentiation into mNK cells, con-
tributing to an accumulation of cells exhibiting a pre-mNK cell
phenotype. As pre-mNK cells exhibit a phenotype reminiscent
of in vitro activated mNK cells and demonstrate high levels of
IFN-γ production as well as most prominent cytotoxic activity
in vitro in short term assays, it is tempting to suggest that pre-
mNK cells play a key role in the regulation of the anti-tumoral
response (22, 27, 28). Clearly, additional studies are required
to fully grasp how pre-mNK cells mediate their remarkable
anti-tumor functions. A combination of their ability to gener-
ate a large number of mNK, as well as their unique functional
attributes, likely contributes to their enhanced anti-tumoral
activity.
5. What are the conditions which are permissive for pre-mNK
cells to present antigens to T cells? Pre-mNK cells were orig-
inally shown to process and present antigens to T cells (21).
This observation, as for IFN-α production, was not repro-
ducibly observed by others, again suggesting that the original
cellular preparations were contaminated with pDC (26, 54).
However, using an intricate in vitro system, pre-mNK cells
were shown to exhibit efficient antigen-presenting potential
when they were co-incubated in the presence of tumoral cells
(59). This antigenic presentation potential of pre-mNK cells
is dependent on their cytolytic potential, namely TRAIL and
NKG2D (21–23, 59). In line with these results, the contact
of pre-mNK cells with tumor cells increases MHC II expres-
sion via an autocrine production of IFN-γ and also enhances
the expression of costimulatory molecules (56). Together, these
studies, which thoroughly compared the antigen-presentation
potential of pre-mNK cells, NK cells, and conventional DCs
to T cells, support the unique antigen-processing and presen-
tation potential for pre-mNK cells (56, 59, 61). Still, it could
be argued that, as pre-mNK cells exhibit a phenotype more
closely related to pDC rather than conventional DC (Figure 1),
it may be relevant to revisit some of these findings in rela-
tion to pDC. Regardless of the debate, the antigen-presentation
potential of pre-mNK cells has been most consistently observed
when pre-mNK cells are exposed to tumoral cells. How and
which tumoral environment enhances the antigen-presentation
potential of pre-mNK cells remain to be established.
6. Do mouse pre-mNK cells and their recently described putative
human equivalent, HLA-DR+ NK cells, truly represent equiv-
alent cell types? No unique markers (whether it be a cell surface
marker, a functional property or a transcription factor neces-
sary for their differentiation) can currently be used to define
pre-mNK cells. Thus, to establish their similitude, comparative
analyses of mouse and human pre-mNK cells must be per-
formed. Importantly, the potential of human pre-mNK cells at
generating mNK cells should be addressed.
7. Can the putative human pre-mNK cells be specifically used as a
cellular therapeutic? There are currently no known factors that
uniquely promote pre-mNK cell numbers in vivo. Although IL-
15 is efficient, it also enhances mNK cells as well as memory
T cells. Pre-mNK cells are difficult to isolate, due to their low
number, and show poor viability in vitro. As to be expected
with the discovery of a novel cell types and notwithstanding
their prominent anti-tumoral potential, there are still many
challenges ahead before pre-mNK cells can effectively be used
in therapy. The most promising current therapeutic avenue
shown to possibly promote pre-mNK cells, which correlates
with improve disease outcome, remains the combination of IM
and IL-2 (32, 53).
CONCLUDING REMARKS
Over the past years, conflicting results on the phenotype and func-
tion of pre-mNK cells highlighted the challenges associated with
defining a cell type present in low number in lymphoid organs. As
the attention focused in defining the lineage origin of pre-mNK
cells, it shifted away from better understanding the striking anti-
tumoral potential of pre-mNK cells. Indeed, murine pre-mNK
cells and the recently proposed human homolog exhibit a promi-
nent anti-tumoral activity. As the field of pre-mNK cell biology
moves forth we anticipate the development of novel therapeutic
approaches in the treatment of cancer and eventually also in the
treatment of other pathologies.
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